Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir-Reference-Cited by-同舟云学术

Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir

Published:2023-03-13 Issue:5 Volume:64 Page:1054-1056
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Tadmor Tamar¹,Melamed Guy²,Patalon Tal²,Alapi Hilel²,Rokach Lior³

Affiliation:

1. Hematology Unit, Bnai Zion Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

2. Kahn Sagol Maccabi (KSM) Research & Innovation Center and Maccabi tech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel

3. Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Funder

KSM- Maccabi Research and Innovation Center

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2183732

Reference9 articles.

1. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir

2. Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19

3. Centers for Disease Control and Prevention (CDC). CDC health alert network. Health advisory. COVID-19 rebound after Paxlovid treatment; 2022, May 24. Available from: https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals;MMWR. Morbidity and Mortality Weekly Report;2023-12-22

2. Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?;Microorganisms;2023-10-22

3. COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?;Acta Haematologica;2023-10-11